- Home
- PCSA vs TTNP Comparison
PCSA vs TTNP Comparison
Compare PCSA & TTNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- TTNP
- Stock Information
- Founded
- PCSA 2011
- TTNP 1991
- Country
- PCSA United States
- TTNP United States
- Employees
- PCSA N/A
- TTNP N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCSA Health Care
- TTNP Health Care
- Exchange
- PCSA Nasdaq
- TTNP Nasdaq
- Market Cap
- PCSA 2.8M
- TTNP 3.4M
- IPO Year
- PCSA N/A
- TTNP 1996
- Fundamental
- Price
- PCSA $0.45
- TTNP $3.53
- Analyst Decision
- PCSA Strong Buy
- TTNP
- Analyst Count
- PCSA 1
- TTNP 0
- Target Price
- PCSA $6.00
- TTNP N/A
- AVG Volume (30 Days)
- PCSA 108.6K
- TTNP 58.5K
- Earning Date
- PCSA 03-28-2025
- TTNP 03-31-2025
- Dividend Yield
- PCSA N/A
- TTNP N/A
- EPS Growth
- PCSA N/A
- TTNP N/A
- EPS
- PCSA N/A
- TTNP N/A
- Revenue
- PCSA N/A
- TTNP N/A
- Revenue This Year
- PCSA N/A
- TTNP N/A
- Revenue Next Year
- PCSA N/A
- TTNP N/A
- P/E Ratio
- PCSA N/A
- TTNP N/A
- Revenue Growth
- PCSA N/A
- TTNP N/A
- 52 Week Low
- PCSA $0.44
- TTNP $3.03
- 52 Week High
- PCSA $3.31
- TTNP $14.80
- Technical
- Relative Strength Index (RSI)
- PCSA 28.60
- TTNP 41.17
- Support Level
- PCSA $0.44
- TTNP $3.81
- Resistance Level
- PCSA $0.54
- TTNP $4.39
- Average True Range (ATR)
- PCSA 0.05
- TTNP 0.47
- MACD
- PCSA 0.00
- TTNP -0.08
- Stochastic Oscillator
- PCSA 8.02
- TTNP 10.42
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.